Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TMV 018

Next Previous
Drug Profile

TMV 018

Alternative Names: TMV-018

Latest Information Update: 28 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Max Planck Institute of Biochemistry; University of Tubingen
  • Developer Themis Bioscience
  • Class Antineoplastics; Cytosine deaminase flucytosine gene therapies; Oncolytic viruses
  • Mechanism of Action DNA synthesis inhibitors; Gene transference; Immunologic cytotoxicity; Prodrug activators; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gastrointestinal cancer

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in Austria (Intratumoural)
  • 05 Dec 2020 Themis Bioscience withdraws the phase I trial for Gastrointestinal cancer (Combination therapy, Monotherapy) in Germany prior to enrolment, as no participants were recruited (IM) (EudraCT2019-003550-88) (NCT04195373)
  • 19 Jun 2020 Themis Bioscience has been acquired by Merck & Co

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top